Full-Time

Senior Project Manager

Custom Antibodies

Twist Bioscience

Twist Bioscience

1,001-5,000 employees

Produces synthetic DNA for research.

Compensation Overview

$128k - $161k/yr

+ Bonus + Equity

San Bruno, CA, USA + 2 more

More locations: Tualatin, OR, USA | Carlsbad, CA, USA

Hybrid

Three days on-site per week required.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Machine Learning
Salesforce
JIRA

Get referred to Twist Bioscience

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Biology, Chemistry, or a related field. An advanced degree or hands-on laboratory experience is a plus.
  • 4–5 years in the life sciences. A technical background in AI/ML based antibody engineering and/or antibody characterization is preferred. Familiarity with Salesforce and Jira is a plus
  • 1–2 years of experience leading scientific projects in a commercial setting, with a proven ability to manage timelines across different departments
  • Collaborative Influence: Ability to work effectively with customers and internal teams (Sales, Operations, Customer & Tech Support, Finance, etc) to move projects forward without direct authority over those teams.
  • Operational Skills: Strong organizational and communication skills, with the ability to meet deadlines and maintain high standards while under pressure.
  • Problem-Solving & Scalability: A track record of identifying bottlenecks in a workflow and implementing practical, organized solutions that help a team handle more volume.
  • Hybrid Work Model: This position follows a hybrid schedule requiring 3 days per week on-site at one of our offices located in Wilsonville, OR; South San Francisco, CA; or Carlsbad, CA.
Responsibilities
  • Manage End-to-End Coordination: Oversee custom AI/ML Antibody projects from intake to final delivery, ensuring smooth transitions between quoting, production, and Antibody data delivery
  • Design & Quoting: Gather antibody design requirements to ensure quotes and SOWs accurately reflect customer needs, accurate costing, and the production team's capabilities.
  • Track & Report: Prepare quotes and maintain real-time status updates in the project tracker for all issued quotations and active orders.
  • Customer Communication: Serve as the primary contact for project timelines, data quality, and technical updates; respond to inquiries or route them to the correct internal expert for prompt follow-up.
  • System Accuracy: Maintain precise records of quotes, orders in progress, and shipments to ensure reliable reporting.
  • Process Improvement: Identify workflow inefficiencies and suggest practical ways to scale operations as the department grows.

Twist Bioscience designs and manufactures synthetic DNA for biotech, pharmaceutical, and research use. It uses a proprietary platform that rapidly produces custom DNA sequences and a smart algorithm to verify synthesis feasibility before production, with customers submitting requests and receiving DNA, DNA data storage, or NGS services. It differentiates itself by offering high-quality DNA at competitive prices, the ability to handle complex sequences, and an integrated platform with a broad product range for fast delivery. Its goal is to be a reliable, leading supplier of synthetic DNA and genomics tools that accelerates biotech and drug development for a wide range of clients.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

2013

Get referred to Twist Bioscience

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q3 fiscal 2026 revenue hit $118.4 million, up 23%, marking 14 straight growth quarters.
  • Management raised fiscal 2026 revenue guidance to $456 million-$457 million on August 3, 2026.
  • AI-enabled drug discovery orders are tracking triple-digit growth in fiscal 2026 and 2027.

What critics are saying

  • August 2026 equity offering diluted holders again after the July 2026 proposed $250 million raise.
  • Legacy securities litigation settlement reaches final hearing November 18, 2026, extending legal distraction.
  • Persistent net losses and dilution threaten profitability if Q4 EBITDA breakeven slips.

What makes Twist Bioscience unique

  • Silicon-based DNA synthesis platform enables complex genes up to 7,000 base pairs.
  • Automated production line delivers 300-7,000 base pair constructs within 15 business days.
  • Twist's hybrid capture portfolio now includes fully automated Fast Hyb on Volta Callisto.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 9th, 2026
Twist Bioscience raises $300M at $96/share after hiking 2026 revenue guidance to $457M

Twist Bioscience raised $300 million through a follow-on stock offering at $96 per share in early August 2026. The synthetic biology company simultaneously increased its fiscal 2026 revenue guidance to $456–457 million and reported third-quarter sales of $118.38 million, though it posted a net loss of $35.05 million. The firm is also working to resolve legacy securities litigation through a proposed $17.05 million class-action settlement. Fourth-quarter revenue guidance stands at $123–124 million. Despite the upgraded outlook, analysts remain cautious about Twist's path to profitability. Some project continued losses alongside approximately 15% annual revenue growth. The company's share price rose 26.3% following the announcements, though concerns about ongoing dilution and losses persist.

Microsoft
Aug 4th, 2026
Twist Bioscience launches $250M public stock offering to fund R&D and manufacturing expansion

Twist Bioscience has launched an underwritten public offering of $250 million of common stock. The synthetic biology company has also granted underwriters a 30-day option to purchase up to an additional $37.5 million of shares. All shares in the offering are being sold by Twist Bioscience. The company plans to use the proceeds to fund research and development investments, expand manufacturing capacity, develop product offerings, and support general corporate purposes.

Yahoo Finance
Aug 3rd, 2026
Twist Bioscience raises guidance to $457M as AI drug discovery drives 23% revenue growth

Twist Bioscience reported fiscal Q3 revenue of $118.4 million, up 23% year over year, marking its 14th consecutive quarter of growth. DNA Synthesis and Protein Solutions revenue rose 39% to $56.6 million, whilst NGS Applications revenue increased 12% to approximately $61.8 million. The company raised its fiscal 2026 revenue guidance to $456 million–$457 million, representing approximately 21% year-over-year growth at the midpoint. Gross margin improved to 52.8%, up 120 basis points sequentially. AI-enabled drug discovery emerged as a significant growth driver. Management expressed confidence in achieving triple-digit order growth in both fiscal 2026 and fiscal 2027. Twist reiterated its expectation to reach adjusted EBITDA breakeven in the fiscal fourth quarter. The company formally launched its Complex Genes offering after early-access customers ordered more than 1,800 constructs.

Yahoo Finance
Jun 19th, 2026
Twist Bioscience gains 153% as tech firms use DNA synthesis for AI genomic databases

Twist Bioscience Corporation has been highlighted as a top contributor by Osterweis Capital Management in its Q1 2026 investor letter. The synthetic DNA manufacturer closed at $87.56 per share on 18 June 2026, with a market capitalisation of $5.45 billion. The company, which produces synthetic genomic material for drug discovery and genomic testing, is positioned in the expanding liquid biopsy field. Notably, Twist is being used by technology companies as an outsourced laboratory for building genomic databases for AI large language models, a new growth area that contributed to strong Q1 performance. Twist's Q2 fiscal 2026 revenue reached $110.7 million, up over 19% year-on-year. Hedge fund holdings increased to 30 portfolios by end of Q1 2026, up from 24 the previous quarter.

Yahoo Finance
Jun 19th, 2026
Eli Lilly and Twist Bioscience use AI to accelerate drug development and growth

Eli Lilly and Twist Bioscience are leveraging AI to accelerate drug development, representing different opportunities in healthcare's AI evolution. Lilly, a pharmaceutical giant dating to the 1870s, is partnering with OpenAI and Nvidia on drug discovery and AI co-innovation labs. Trading near $1,120, Lilly shares have gained 36% over the past year and over 400% in five years. First-quarter 2026 revenue jumped 56% to $19.8 billion, whilst net income climbed 168% to $7.4 billion. The company's newly approved weight-loss pill, Foundayo, could significantly expand its patient base. Twist Bioscience, founded in 2013, produces synthetic DNA for pharmaceutical testing. Its shares trade around $83, up 136% over the past year, though down 26% over five years, presenting a higher-risk growth opportunity.